Neil Woodford has ditched half his FTSE 100 holdings!

Is Neil Woodford making the biggest conviction bet of his career?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s a bit over two years since Neil Woodford left Invesco Perpetual and set up his own asset management business. The CF Woodford Equity Income Fund he launched in June 2014 was almost a replica of the one he’d left behind at Invesco.

The new fund was initially dominated by 17 familiar FTSE 100 names and half-a-dozen US and European megacaps, which together accounted for almost three-quarters of the weight of the portfolio.

However, over the past couple of years, Woodford has ditched blue chip after blue chip. The number of international giants has been reduced to just two, while the following nine FTSE 100 companies have disappeared from the portfolio:

  • BAE Systems, Meggitt and Rolls-Royce (aerospace & defence)
  • Centrica and SSE (utilities)
  • BT (telecommunications)
  • HSBC (banks)
  • Reckitt Benckiser (consumer goods)
  • Smith & Nephew (healthcare)

Today, Woodford’s equity income fund holds just nine FTSE 100 stocks (one of which was in the FTSE 250 when he bought it).

I can’t recall a previous occasion when Woodford has shunned over 90% of the companies in the FTSE 100. While he’s never been afraid to pull out of some sectors of the market at certain times, there are currently whole swathes of the Footsie to which he has little or no exposure. His retained blue chip holdings tell a story of extraordinarily limited diversification by industry:

  • AstraZeneca and GlaxoSmithKline (big pharma)
  • British American Tobacco and Imperial Brands (tobacco)
  • Legal & General and Provident Financial (financials)
  • Babcock International and Capita (outsourcing)
  • Next (retail)

So where is he investing now?

The reduction in the number of blue chip holdings and the increased sector concentration of the retained positions has been dramatic. Equally striking though, is where Woodford’s invested the money he’s pulled out of FTSE 100 firms.

We’ve seen dozens and dozens of smaller companies added to the equity income fund with an overarching theme of technology — particularly biotechnology. Even many of the holdings classified as financials or industrials are, in fact, incubators of small technology companies.

And, of course, the second fund Woodford launched in April 2015 — Woodford Patient Capital Trust — is also very much all about these types of companies (he soon dropped a handful of FTSE 100 stocks that figured in the trust’s portfolio early on).

So what’s behind Woodford’s huge move into this area? He wrote in March last year: “Increasingly, innovation in the pharmaceutical industry is being driven by what was learnt and then built on 15 years ago with the decoding of the human genome. The market was right to be excited by this important and exciting scientific breakthrough — it was just wrong on the timing.”

He reckons the time is now ripe for businesses operating directly in this field, or in areas associated with it, to start delivering profound and positive benefits for investors and patients alike — and he’s backing his judgement on this to the hilt.

The dramatic reduction of FTSE 100 holdings and mushrooming of exposure to the small-cap technology theme represent, I’d suggest, the biggest conviction bet of Woodford’s career.

It’s going to be interesting to see how this plays out, and it’s certainly giving me food for thought about where the best opportunities for investors might be found in the market today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca, Centrica, HSBC Holdings, Meggitt, and Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »